anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to use of GPI-PLD antagonists for the prevention, treatment and diagnosis of pre-eclampsia. The substantial GPI-PLD  activity is present in the placenta in pre-eclampsia is not expressed in the placenta, but rather is taken up from the maternal circulation. As a result, abnormal or dysregulated GPI-PLD activity present in the placenta in pre-eclampsia may be correctable by administration of GPI-PLD to the mother to correct the problems caused by abnormal or dysregulated GPI-PLD, e.g. to reduce the abnormal release and in situ production of placental IPGs involved in the pathogenesis of pre-eclampsia. This can be achieved using exogenous GPI-PLD or a fragment thereof, e.g. an inactive GPI-PLD capable of competing with or displacing the abnormal or dysregulated GPI-PLD, e.g. from Apo-A1.
Wide surgical removal of the tumor with the addition of a systemic treatment based on the antineoplastic drugs active against osteosarcoma (Adriamycin, Cisplatin, Ifosfamide, Methotrexate). The use of radiation therapy will be given to patients with unresectable tumors. It is recommended in patients who underwent inadequate surgical removal of the tumor. The addition of radiation therapy can not compensate for an adequate surgical treatment.

All the patients eligible for the study will receive the planned systemic treatment. Depending on clinical features, and feasibility of adequate surgical removal of the tumor, patients may receive primary chemotherapy followed by a postoperative chemotherapy treatment or only an adjuvant chemotherapy. In case of immediate surgery, patients will receive an adjuvant treatment with the 3-drug regimen (Cisplatin-Adriamycin-Ifosfamide).
The invention discloses a Tribonema sp. PD2 strain with a preservation number of CGMCC No.10488, and application thereof in the production of biodiesel, palmitoleic acid, feed, food, skin care products, and therapeutic drugs for cardiovascular and cerebrovascular diseases, and in the carbon dioxide emission reduction, and waste gas treatment and/or wastewater treatment. The Tribonema sp. PD2 strain has the advantages of fast growth, high biomass and easiness in harvesting, and is suitable for industrial application. The oil content of the Tribonema sp. PD2 strain is as much as 60% or more of the dry biomass, wherein the content of C16-C18 is as much as 85% of the total fatty acids, the content of the palmitoleic acid (C16:1omega7) is no less than 45% of the total fatty acids, and the content of the total unsaturated fatty acids is as much as 65% of the total fatty acids. Therefore the Tribonema sp. PD2 strain is especially suitable for the production of biodiesel and the development of health care products and foods.
INTRODUCTION: Enhanced recovery after surgery (ERAS) has been increasingly adopted in orthopaedic surgery. Although not an exclusion criterion, patients undergoing total knee arthroplasty (TKA) with preoperative severe varus deformity may be less likely to be enrolled for ERAS. This study aimed to compare the success of ERAS TKA between patients with severe preoperative varus deformities (≥ 15° varus) and the control group (< 15° varus to 14° valgus). Our secondary aim was to compare postoperative complications and functional outcomes between the two groups.
MATERIALS & METHODS: 310 TKAs performed from August 2019 to February 2021 were analyzed with a follow-up of 6 months postoperatively. The primary outcome, ERAS TKA success, was defined as length of hospital stay of < 24 h. Other parameters included 30-day postoperative complications and clinical outcomes such as the original Oxford Knee Score (OKS), the Knee Society Knee (KSKS) and Function Score (KSFS), Visual Analog Scale for Pain (VAS-P), 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS) and SF-36 Mental Component Summary (MCS).
RESULTS: There were 119 patients in the severe deformity group and 191 patients in the control group. There were no significant differences in ERAS success between the severe deformity group and control group, with both groups achieving similarly high rates (> 90%) of ERAS success. There were also no differences in 30-day postoperative complications and 6-month postoperative clinical outcomes.
CONCLUSION: Patients with severe preoperative varus deformity undergoing ERAS TKA achieved high ERAS success rates (> 90%). Genu varum is not a contraindication for ERAS TKA.
Tramadol hydrochloride tablets, for oral use, are an opioid agonist. The chemical name for tramadol hydrochloride is (±) cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. The structural formula is: 

The molecular weight of tramadol hydrochloride is 299.84. Tramadol hydrochloride is a white, crystalline powder. It is freely soluble in water and in methanol, very slightly soluble in acetone and has a pKa of 9.41. Tramadol hydrochloride tablets contain 50 mg of tramadol hydrochloride (equivalent to 43.9 mg of tramadol) and are white in color. Inactive ingredients in the tablet are colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, opadry white, sodium starch glycolate. The opadry white contains HPMC 2910/Hypromellose 3 mPas and 6 mPas, Macrogol, Polysorbate 80 and Titanium Dioxide.
Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 25 µg/kg GE will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
The invention discloses a traditional Chinese medicine for treating woman infertility, which comprises the following raw material medicines in parts by weight: 10 parts of fructus evodiae, 12 parts of angelica sinensis, 9 parts of Ligusticum wallichii, 12 parts of wine radix paeoniae alba, 12 parts of codonopsis pilosula var. modesta, 10 parts of cassia twig, 12 parts of donkey-hide gelatin beard, 10 parts of cortex moutan radicis, 12 parts of Liriope spicata, 10 parts of Rhizoma Pinellinae Praeparata and 10 parts of radix glycyrrhizae preparata. The traditional Chinese medicine can be made into all clinically acceptable preparations for oral administration. The traditional Chinese medicine for treating woman infertility is taken 10 days before menses. The efficiency is 86% in 200 outpatient cases. The invention has the advantages of no toxic or side effects, good tolerance, obvious curative effect and low treatment cost.
Futibatinib is an irreversible inhibitor of fibroblast growth factor receptors and is currently the subject of phase II clinical trials for the treatment of metastatic carcinomas. We report a case of a 59-year-old woman with metastatic malignant breast cancer who developed acute symptomatic subretinal fluid (SRF) accumulation after two weeks of futibatinib therapy. The SRF resolved within two weeks after futibatinib cessation. The medication was subsequently restarted at a lower dose, and SRF recurred within two weeks. To our knowledge, this is the first case depicting rapidly reversible SRF accumulation with the use of futibatinib in a real-world clinical setting. [Ophthalmic Surg Lasers Imaging Retina 2024;55:109-111.].
PURPOSE:The titled liposome having a membrane, constituting the liposome, and consisting of a lipid containing a specific amount of an ascorbic acid ester. CONSTITUTION:An improved liposome obtained by reinforcing a membrane constituting the liposome with a lipid, e.g. a phospholipid such as phosphatidyl choline, containing 0.1-20mol% ascorbic acid ester, e.g. higher mono- or diester of ascorbic acid. The liposome membrane is reinforced since the ascorbic acid enters between the bimolecular membranes of the lipid by addition of the ascorbic acid ester to the lipid constituting the liposome membrane and the hydrogen bonding zone is reinforced along with the hydrophobic bond. If the lipid contains an unsaturated carboxylic acid, the oxidation thereof is prevented. A sterol, e.g. cholesterol, may be added thereto to enhance further the strength of the membrane, and another electrically charged material, fat-soluble drug, etc. can be added thereto.
Creating a macro profile of an entity is disclosed. Attribute data associated with an entity is identified from (1) one or more public domain information sources and/or (2) one or more private domain information sources. One or more micro profiles for the entity are generated based on the identified data, each of the micro profiles describing the entity in a single dimension. Transactions associated with the entity and/or interactions between the entity and one or more other entities are monitored. A plurality of the generated micro profiles for the entity is selected. The selected micro profiles are associated to generate a macro profile for the entity, the macro profile describing the entity in multiple dimensions. The monitored transactions and/or monitored interactions are analyzed to identify any discrepancies in the macro profile. The macro profile is updated to account for the identified discrepancies.
Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
OBJECTIVE: To evaluate the feasibility, safety, and efficacy of massive continuous irrigation (MCI) and endoscopic debridement for the treatment of refractory abscess-fistula complexes.
METHODS: This was a retrospective single-center observational study involving 12 patients with refractory abscess-fistula complexes. All patients had experienced long-term treatment failure or had failed multiple treatment modalities. We used over two catheters and inserted them via the gastrointestinal (GI) tract or percutaneously to form a circulation pathway to achieve MCI of normal saline, endoscopic debridement was then performed. The treatment success rate, irrigation volume and treatment duration, time to abscess-fistula complex closure, intra-treatment complications, and recurrence rate were recorded.
RESULTS: The treatment success rates were 100%. The median time of previous treatment was 32 days (range 7-912 days). The mean time from the use of the novel treatment strategy to abscess-fistula complex healing was 18.8 ± 11.0 days. The mean volume of irrigation was 10 804 ± 1669 mL/24 h. The mean irrigation time was 16.5 ± 9.2 days, and a median of two irrigation tubes (range 2-5) were used. No complications occurred either during or after the procedure. During the follow-up of 23.1 ± 18.1 months, no recurrence or adverse events were noted.
CONCLUSIONS: MCI and endoscopic debridement may be a feasible, safe, and effective alternative treatment for refractory abscess-fistula complexes. Large prospective studies are needed to validate our results.
The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.
Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
1316362 Aminoalkyl acridan derivatives ROUSSEL UCLAF 28 May 1970 [28 May 1969] 52980/72 Divided out of 1316361 Heading C2C The invention comprises compounds of the formula wherein R 1  is a C 1  to C 4  alkyl group, R 2  is H or a C 1  to C 4  alkyl group and X and X<SP>1</SP> are each a H or halogen atom. They may be obtained by reducing a compound of the formula wherein Alk represents a C 1  to C 4  alkyl group. Specified reducing agents are LiAlH 4 , AIH 3 , diborane, an organo-aluminium hydride or an organo-aluminium. Examples are given for the preparation of the compounds. Compounds of Formula II may be obtained by reacting a compound of formula with an amine of formula wherein Hal is Cl, Br or I, in the presence of an alkali metal or an alkali metal alcoholate. Examples are given for the preparation of these compounds.
OBJECTIVE: Craniovertebral junction (CVJ) abnormalities are common and well documented in mucopolysaccharidosis type I-Hurler syndrome (MPS IH), often causing severe spinal canal narrowing. However, the requirement for surgical decompression and/or fusion is uncommon. Although hematopoietic cell transplant (HCT) has been shown to prolong the lives of patients with MPS IH, its effect in halting or reversing musculoskeletal abnormalities is less clear. Unfortunately, there are currently no universal guidelines for imaging or indication for surgical interventions in these patients. The goal of this study was to track the progression of the CVJ anatomy in patients with MPS IH following HCT, and to examine radiographic features in patients who needed surgical intervention.
METHODS: Patients with MPS IH treated at the University of Minnesota with allogeneic HCT between 2008 and 2020 were retrospectively reviewed. Patients who underwent CVJ surgery were identified with chart review. All MPS IH cervical scans were examined, and the odontoid retroflexion angle, clivoaxial angle (CXA), canal width, and Grabb-Oakes distance (pB-C2) were measured yearly for up to 7 years after HCT. Longitudinal models based on the measurements were made. An intraclass correlation coefficient was used to measure interrater reliability. Nine children without MPS IH were examined for control CVJ measurements.
RESULTS: A total of 253 cervical spine MRI scans were reviewed in 54 patients with MPS IH. Only 4 (7.4%) patients in the study cohort required surgery. Three of them had posterior fossa and C1 decompression, and 1 had a C1-2 fusion. There was no statistically significant difference in the spinal parameters that were examined between surgery and nonsurgery groups. Among the measurements, canal width and CXA varied drastically in patients with different neck positions. Odontoid retroflexion angle and CXA tended to decrease with age. Canal width and pB-C2 tended to increase with age.
CONCLUSIONS: Based on the data, the authors observed an increase in canal width and pB-C2, whereas the CXA and odontoid retroflexion angle became more acute as the patients aged after HCT. The longitudinal models derived from these data mirrored the development in children without MPS IH. Spinal measurements obtained on MR images alone are not sufficient in identifying patients who require surgical intervention. Symptom monitoring and clinical examination, as well as pathological spinal cord changes on MRI, are more crucial in assessing the need for surgery than is obtaining serial imaging.
A purpose of the present invention is to provide a novel composition capable of improving athletic performance. The present invention provides a composition for improving athletic performance, which includes [alpha]-cyclodextrin as an active ingredient. The athletic performance improvement comprises at least one action selected from body force improvement, anti-fatigue, and fatigue feeling decrease. Further, the athletic performance improvement includes inhibition of heartbeat number from increasing at exercise. The present invention also provides a proliferating composition for Bacteriodes niformis in the intestine, which includes [alpha]-cyclodextrin as an active ingredient. In the present invention, [alpha]-cyclodextrin is preferable administered in an amount of 0.01 mg/kg body weight to 200 mg/kg body weight per day, and is preferably administered at least 7 days.
BACKGROUND: Changes in lifestyle and dietary habits that hunter-gatherer populations have undergone in recent decades have often led to rising obesity rates with disastrous consequences for their health.
OBJECTIVES: The associations between dietary habits and weight status were studied in 238 "Ju/'hoansi" San (93 women and 145 men) aged between 18 and 65 years in northern Namibia in 1987. Weight status was estimated based on the World Health Organization body mass index (BMI) categories, and dietary habits were recorded using food recall methods. Anthropometrics and weight status were compared with those of a sex- and age-matched sample of "Ju/'hoansi" San people collected by Nancy Howell in 1968/69.
RESULTS: Body weight had increased significantly among "Ju/'hoansi" San people from 1968/69 to 1987. The number of underweight people decreased from 1968/69 to 1987. In 1987, most participants (60.9%) were of normal weight. Overweight was found in 1.3% of the women, but not among men. No participants were obese. Less than 4% of the women and less than 2% of the men consumed exclusively traditional hunter-gatherer food. Westernized food products were significantly (p < 0.001) more common among men and younger people. Dietary patterns were significantly associated with weight status. The less traditional the diet, the higher the BMI (p < 0.001).
CONCLUSION: The transition to domestic agricultural and westernized foods was positively associated with increasing BMI. Overweight, however, was still an extremely rare condition in this population in 1987.
This study will be an open-label, randomized, 4-period, 4-treatment, cross-over, single-center, single-dose study to assess the relative bioavailability of different formulations of ticagrelor in approximately 44 healthy adult subjects. Eligible subjects will be healthy male and female aged 18 to 55 years, with a body weight of 55 to 100 kg and a body mass index (BMI) of 18 to 30 kg/m2. Of the 44 randomized subjects, at least 36 evaluable subjects should be at the end of the last treatment period. Subjects will be randomized to 1 of 4 treatment sequences and will receive single oral doses of 4 different formulations of ticagrelor under fasted conditions. Subjects will fast for at least 10 hours prior to administration of Investigational Medicinal Products (IMPs). No fluids will be allowed apart from water which can be given until 1 hour prior to administration of the IMP and then from 2 hours after administration of the IMP. A meal can be given 4 hours after administration of the IMP.
The present invention describes chimeric vaccine antigens against the virus that causes classical swine fever (CSFV). Said vaccine antigens are based on viral subunits that are coupled to protein molecules that stimulate not only the cellular but also the humoral immune system. The chimeric antigens may by produced in expression systems that guarantee correct three-dimensional folding of the chimeric molecules that constitute the basis of the present invention. The vaccine compositions that contain said chimeric antigens induce a potent, early immune response in vaccinated pigs, conferring total protection against CSFV. In addition, the resulting vaccine compositions prevent viral transmission from sow to progeny. The chimeric antigens, and also the resulting vaccine compositions, are applicable to the field of animal health as vaccines for preventive use in swine. ® KIPO & WIPO 2009
One hundred patients with Alzheimer's disease were included, mainly from geriatric neurology outpatient clinics and wards (F5A \& F6A). Inclusion criteria: patients with Alzheimer's disease, meeting the IWG-2 clinical diagnostic criteria as the basis. Exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and postoperative neurosurgery; ② severe psychiatric illnesses that are difficult to cooperate with.
Cosmetic preparations (I) contain esters of di- and poly-basic aliphatic hydroxycarboxylic acids (3-6C) with aliphatic- or alicylic alcohols (1-6C) at 1-50 pref. 5-30% of the total preparation. (I) may be used in the treatment and prophylaxis of acne. (I) have no adverse effects on the sking of patients, even those with sensitive skins. The esters used are prepd. in known ways by azeotropic esterification of the signified acids and alcohols.
Participants with serum 25(OH)D levels below 12 ng/mL, receiving 60 cc. MCT supplement.
Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully understood. Following LT, patients have an increased incidence of atherosclerotic CVD. Notably, atherosclerotic CVD is an established risk factor for diastolic dysfunction and incident heart failure with preserved ejection fraction (HFpEF). There is a critical need to better understand the biological mechanisms of LT related vascular dysfunction and establish targeted interventions that will reduce the risk of CVD in this patient population. In the general population, there is strong epidemiological evidence linking high TMAO levels with atherosclerotic CVD and heart failure, and that it can modulated rapidly by diet within two weeks. Therefore, the purpose of this study is to better understand the role of TMAO in cardiovascular dysfunction patients with chronic kidney disease.
Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.
PURPOSE: A composition containing Morus bombycis extract with an anti-allergic effect is provided to suppress allergen secretion and TNF-alpha and IL-4. CONSTITUTION: A pharmaceutical composition for preventing and treating allergic diseases contains Morus bombycis water extract as an active ingredient. The allergic diseases are allergic rhinitis, allergic conjunctivitis, atopic asthma, allergy desmatitis, and allergic urticaria. A pharmaceutical composition contains Morus bombycis contains Morus bombycis organic solvent extract as an active ingredient. The organic solvent is methanol, ethanol, propanol, or butanol. A method for preparing the composition comprises: a step of heating Morus bombycis in hot water, and a step of filtering and concentrating the extract.